Renaissance Technologies
PLX icon

Renaissance Technologies’s Protalix BioTherapeutics PLX Stock Holding History

Renaissance Technologies’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.66M Sell
1,224,800
-38,500
-3% -$95.5K ﹤0.01% 1728
2025
Q4 		$2.27M Sell
1,263,300
-52,100
-4% -$107K ﹤0.01% 1783
2025
Q3 		$2.92M Sell
1,315,400
-299,603
-19% -$488K ﹤0.01% 1812
2025
Q2 		$2.39M Buy
1,615,003
+426,050
+36% +$872K ﹤0.01% 2005
2025
Q1 		$3.04M Buy
1,188,953
+70,953
+6% +$169K ﹤0.01% 1731
2024
Q4 		$2.1M Buy
1,118,000
+162,100
+17% +$229K ﹤0.01% 2017
2024
Q3 		$975K Buy
955,900
+151,300
+19% +$159K ﹤0.01% 2459
2024
Q2 		$941K Sell
804,600
-20,100
-2% -$23.7K ﹤0.01% 2356
2024
Q1 		$1.04M Buy
824,700
+159,100
+24% +$238K ﹤0.01% 2463
2023
Q4 		$1.19M Buy
665,600
+44,500
+7% +$69.2K ﹤0.01% 2295
2023
Q3 		$1.03M Sell
621,100
-38,200
-6% -$68.6K ﹤0.01% 2273
2023
Q2 		$1.32M Sell
659,300
-550,450
-46% -$1.31M ﹤0.01% 2284
2023
Q1 		$2.54M Buy
1,209,750
+985,147
+439% +$1.73M ﹤0.01% 1878
2022
Q4 		$308K Buy
224,603
+107,403
+92% +$118K ﹤0.01% 3207
2022
Q3 		$122K Buy
117,200
+2,400
+2% +$2.66K ﹤0.01% 3531
2022
Q2 		$125K Buy
114,800
+102,900
+865% +$120K ﹤0.01% 3792
2022
Q1 		$13K Buy
+11,900
New +$10.9K ﹤0.01% 4019
2021
Q3 		– Sell
-30,075
Closed -$57K – 3756
2021
Q2 		$57K Sell
30,075
-477,559
-94% -$1.64M ﹤0.01% 3386
2021
Q1 		$2.26M Buy
507,634
+19,000
+4% +$88.5K ﹤0.01% 2138
2020
Q4 		$1.77M Sell
488,634
-1,700
-0.3% -$6.09K ﹤0.01% 2193
2020
Q3 		$1.9M Sell
490,334
-40,100
-8% -$145K ﹤0.01% 2168
2020
Q2 		$2.01M Buy
530,434
+53,000
+11% +$181K ﹤0.01% 2181
2020
Q1 		$1.12M Buy
477,434
+17,800
+4% +$58.9K ﹤0.01% 2373
2019
Q4 		$1.51M Buy
459,634
+14,587
+3% +$35.9K ﹤0.01% 2447
2019
Q3 		$913K Buy
445,047
+12,394
+3% +$37K ﹤0.01% 2641
2019
Q2 		$2.03M Buy
432,653
+30,882
+8% +$130K ﹤0.01% 2321
2019
Q1 		$1.77M Buy
401,771
+31,474
+8% +$142K ﹤0.01% 2374
2018
Q4 		$1.15M Buy
370,297
+43,657
+13% +$207K ﹤0.01% 2503
2018
Q3 		$2.37M Buy
326,640
+65,170
+25% +$327K ﹤0.01% 2194
2018
Q2 		$1.12M Buy
261,470
+30,520
+13% +$136K ﹤0.01% 2555
2018
Q1 		$1.25M Buy
230,950
+31,600
+16% +$208K ﹤0.01% 2564
2017
Q4 		$1.32M Sell
199,350
-10,780
-5% -$72.7K ﹤0.01% 2553
2017
Q3 		$1.22M Sell
210,130
-19,950
-9% -$128K ﹤0.01% 2501
2017
Q2 		$1.93M Buy
230,080
+37,330
+19% +$350K ﹤0.01% 2285
2017
Q1 		$2.62M Buy
192,750
+144,820
+302% +$1.3M ﹤0.01% 2093
2016
Q4 		$213K Buy
47,930
+29,840
+165% +$133K ﹤0.01% 2985
2016
Q3 		$103K Buy
18,090
+7,800
+76% +$48.6K ﹤0.01% 3175
2016
Q2 		$66K Buy
10,290
+4,800
+87% +$38.4K ﹤0.01% 3209
2016
Q1 		$46K Buy
5,490
+3,397
+162% +$29.1K ﹤0.01% 3286
2015
Q4 		$21K Buy
+2,093
New +$21.3K ﹤0.01% 3224

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies's PLX Position: Q1 2026 in Review

Renaissance Technologies reduced its Protalix BioTherapeutics (PLX) stake by 3% in Q1 2026, selling an estimated $95.5K and leaving 1,224,800 shares worth $2.66M. The position accounts for ﹤0.01% of the portfolio, ranked #1728.

Renaissance Technologies first reported a position in PLX in Q4 2015 and has held it in 40 quarters since. The position peaked at $3.04M in Q1 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Renaissance Technologies held 1,224,800 shares of Protalix BioTherapeutics worth $2.66M as of Q1 2026.
  • Renaissance Technologies sold 38,500 Protalix BioTherapeutics shares in Q1 2026, an estimated $95.5K.
  • Protalix BioTherapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #1728 holding.
  • Renaissance Technologies first reported a position in Protalix BioTherapeutics in Q4 2015 and has held it in 40 quarters since.
  • Renaissance Technologies's Protalix BioTherapeutics position peaked at $3.04M in Q1 2025.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.